Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Fas-dependent tissue turnover is implicated in tumor cell clearance

Abstract

The apoptosis-inducing Fas receptor has been shown to be down-regulated in various types of tumors, while its ligand (FasL) appears to be frequently up-regulated. Here we provide evidence that there is a strong selective pressure in vivo against Fas-expressing, tumorigenic NIH3T3 cells, favoring survival, proliferation and eventually tumor formation by Fas-negative cells. Importantly, re-expression of Fas in these cells results in either the complete abolishment of tumor development, or in a significant extenuation of the latency period of tumor outgrowth. In addition, we found that environmental conditions which prevail during tumorigenesis, such as limiting amounts of survival factors and the lack of cell adhesion, are markedly sensitizing tumor cells to Fas-mediated suicide. Our data suggest that in addition to T cell-mediated immune responses, mechanisms of Fas-dependent tissue turnover are also centrally implicated in tumor cell clearance.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  • Abbas AK . 1996 Cell 84: 655–657

  • Butler LM, Hewett PJ, Butler WJ and Cowled PA . 1998 Br J Cancer 77: 1454–1459

  • Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS and Reed JC . 1998 EMBO J 17: 2215–2223

  • Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P and Grandien A . 1999 J Exp Med 190: 1025–1031

  • Faris M, Kokot N, Latinis K, Kasibhatla S, Green DR, Koretzky GA and Nel A . 1998 J Immunol 160: 134–144

  • French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, Muller C and Tschopp J . 1996 J Cell Biol 133: 335–343

  • Frisch SM and Francis H . 1994 J Cell Biol 124: 619–626

  • Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J and Tschopp J . 1996 Science 274: 1363–1366

  • Hill LI, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN and Owen-Schaub LB . 1999 Science 285: 898–900

  • Hueber AO, Zornig M, Lyon D, Suda T, Nagata S and Evan GI . 1997 Science 278: 1305–1309

  • Irmler M, Thorne M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JI, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J . 1997 Nature 388: 190–195

  • Lebel M, Bertrand R and Mes-Masson AM . 1996 Oncogene 12: 1127–1135

  • Medema JP, de Jong J, van Hall T, Melief CJM and Offringa R . 1999 J Exp Med 190: 1033–1038

  • Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A and Krammer PH . 1994 J Cancer 57: 371–377

  • Nagata S . 1997 Cell 88: 355–365

  • Nagata S and Golstein P . 1995 Science 267: 1449–1456

  • Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E and Tschopp J . 1999 EMBO J 18: 1824–1831

  • Robertson MJ, Manley TJ, Pichert C, Cameron C, Cochran KJ, Levine H and Ritz J . 1995 Leuk Lymph 17: 51–61

  • Shinoura N, Yoshida Y, Nishimura M, Muramatsu Y, Asai A, Kirino T and Hamada H . 1999 Cancer Res 59: 4119–4128

  • Srivastava RK, Sasaki CY, Hardwick JM and Longo DI . 1999 J Exp Med 190: 253–265

  • Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR . 1996 Nature Med 2: 1361–1366

  • Suzuki A, Enari M, Eguchi Y, Matsuzawa A, Nagata S, Tsujimoto Y and Iguchi T . 1996 EMBO J 15: 211–215

  • Thompson CB . 1995 Science 267: 1456–1462

  • Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B and Kalthoff H . 1998 Cancer Res 58: 1741–1749

  • Walker PR, Saas P and Dietrich PY . 1997 J Immunol 158: 4521–4524

  • Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin ASJ . 1998 Science 281: 1680–1683

  • Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA and Nagata S . 1992 Nature 356: 314–317

Download references

Acknowledgements

We thank Drs R Iggo, R Budds, A Quest and C Ware for helpful comments. This research was supported by the Swiss National Science Foundation (E Reichmann) and the Krebsforschung Schweiz (J Peli and E Reichmann).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schröter, M., Peli, J., Hahne, M. et al. Fas-dependent tissue turnover is implicated in tumor cell clearance. Oncogene 19, 1794–1800 (2000). https://doi.org/10.1038/sj.onc.1203499

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203499

Keywords

  • tumorigenesis
  • Fas-signaling
  • caspase activity
  • apoptosis
  • immune response
  • tissue turnover

Search

Quick links